Dr. Ahmed Physicians are commonly prescribing Mounjaro and Ozempic for weight loss to overweight individuals without diabetes.
While some may view this as a misuse of these drugs, most experts believe there isn’t anything inherently wrong with it.
Both Tirzepatide (Mounjaro) and Semaglutide (Ozempic) are approved for diabetes and weight loss. Changing their names for marketing purposes might not significantly influence decision-making by physicians, especially those operating weight loss clinics.
For readers unfamiliar with the distinction between prescribing Semaglutide and Tirzepatide for weight loss versus diabetes, here is an easy guide:
Semaglutide is available as:
- Ozempic: Once-weekly injections, FDA-approved for diabetes.
- Wegovy: Once-weekly injections, FDA-approved for weight loss.
- Rybelsus: Once-daily oral tablets, FDA-approved for diabetes.
Both Ozempic and Wegovy are the same drug with the same administration schedule and side effect profile. However, for diabetes control, the maximum recommended dose of Ozempic is 2 mg [Ref], while for weight loss, the maximum recommended dose of Wegovy is 2.4 mg.
Tirzepatide is available as:
- Mounjaro: Once-weekly injections, FDA-approved for managing diabetes.
- Zepbound: Once-weekly injections, FDA-approved for weight loss.
There is no difference in the dosing schedule, dose, or side effects between Mounjaro and Zepbound. The only difference is their names.
For pharmaceutical and insurance companies, these distinctions might be significant. However, for patients and physicians, it doesn’t matter whether you inject Mounjaro or Zepbound, Ozempic or Wegovy.
In fact, most people now use these drugs for weight loss rather than for diabetes.
The only argument in favor of using the approved brands for weight loss and diabetes, respectively, is to ensure that those who need these drugs the most—obese individuals with diabetes—can access them.
On the 23rd of July 2024, a nationwide study showed how the use of GLP-1 RAs has significantly shifted.
The rise of GLP-1 agonists
The need for GLP-1 receptor agonists (GLP-1 RAs) has greatly increased recently because they work very well for managing weight and treating diabetes.
This rise in popularity has led to more production and a variety of GLP-1 RA options.
Drug companies are constantly improving to meet the growing demand as they have provided options from the first injectable forms like liraglutide and semaglutide to newer oral versions.
Since there are multiple ways you can take GLP-1 RAs, it has made it much easier for people to access and use them.
This study was published in the Annals of Internal Medicine, and it showed a new trend in the use of these drugs.
While we see that new prescriptions for GLP-1 RAs for T2DM have gone down, there is also a rise in the number of prescriptions for obesity and related conditions.
This shows that more and more people are recognising the drug’s potential to help with weight loss.
A double-edged sword
The growing popularity of GLP-1RAs is definitely good news, as these meds have shown to be very effective in helping people lose weight and improve their health.
However, the quick increase in demand has caused some problems, and there are now shortages of popular GLP-1RAs, making it hard for some people to get them.
Furthermore, the study also points out that there are differences in how commonly these drugs are prescribed based on race and ethnicity, which raises concerns about fairness in healthcare.
Methodology and Data Analysis:
This study used a nationwide retrospective cohort design to use data from a large commercial claims database.
Subjects aged 18 years or older who started GLP-1RA therapy between January 1, 2017, and December 31, 2021, were included in this research.
The main goal was to see the proportion of new GLP-1RA prescriptions for obesity compared to type 2 diabetes over time. They also looked at changes in prescription rates by age, sex, race, and ethnicity.
The study found that new GLP-1RA prescriptions for obesity went up a lot, from 12.5% in 2017 to 32.7% in 2021.
At the same time, new prescriptions for type 2 diabetes went down from 87.5% to 67.3%.
Prescription rates varied by different demographic factors, with higher rates among younger, female, and white patients.
| Year | New Prescriptions for Obesity | New Prescriptions for Type 2 Diabetes |
| 2017 | 12.5% | 87.5% |
| 2018 | 15.3% | 84.7% |
| 2019 | 20.1% | 79.9% |
| 2020 | 25.4% | 74.6% |
| 2021 | 32.7% | 67.3% |
Through this analysis, we can clearly see that people are leaning toward the use of GLP-1 RAs for weight management.
Even though this trend shows how effective GLP-1 RAs are still, there are concerns about the possible inequalities in access and use.
The future of GLP-1RAs
The pharmaceutical industry is meeting the rising demand for GLP-1RAs by creating new and better medications. Researchers are also looking into other uses for these drugs, like lowering the risk of heart problems [ref].
As more people use GLP-1RAs, it is important to keep an eye on their long-term effects and possible side effects.
Healthcare providers also need to make sure everyone who can benefit from these medications has access to them.
Through this study, we can see that more research is required to learn about the best way GLP-1 RAs can be used for weight management and diabetes care.
By understanding how GLP-1RA prescriptions are changing, healthcare professionals can better help patients and improve treatment results.
Takeaway:
These drugs were originally meant for diabetes, but they have gained so much popularity among obese people.
Because of their mechanism of action and their impact on both appetite and blood sugar levels, they have completely changed the way obesity and T2DM are treated.
Still, we are facing challenges regarding the availability, shortage, and fair access to these, as the study revealed that white people, females, and younger individuals are more likely to get a prescription.
Nevertheless, as the use of GLP-1 RAs is rising, it is important to keep an eye on its long-term effectiveness and other side effects.
